Company news

Racura Oncology Ltd news in 2024

Racura Oncology Ltd's news releases, calls and decks from 2024, newest first.

View company

Race Receives $5.25m RD Tax Refund for Financial Year 2024

December 16, 2024

Race Submits Human Ethics for RC220 Phase 1 Trial

December 4, 2024

Race Discovers Multiple Novel FTO Inhibitor Candidates

November 20, 2024

Race Oncology Board Renewal Update

September 1, 2024

Bisantrene Phase 2 AML Trial Successful Concludes

July 29, 2024

RC220 GLP Non-clinical Toxicology Program Successful

June 25, 2024

Race Appoints George Clinical for Phase 1 Trial of RC220

June 19, 2024

FDA RPD Designation Granted for RC220 Bisantrene

June 17, 2024

Bisantrene Highly Active in a Multiple Myeloma Mouse Model

June 12, 2024

US FDA Orphan Drug Designation Awarded to RC220 Bisantrene

June 10, 2024

Bisantrene with Decitabine Enhances Cancer Cell Killing

May 13, 2024

Quarterly Activity Report & Appendix 4C

April 18, 2024

RC220 cGMP Manufacturing Complete

March 25, 2024

Bisantrene shows potent anticancer activity in AML models

March 5, 2024

S&P DJI Announces March 2024 Quarterly Rebalance

March 1, 2024

Race Receives $4.0m R&D Tax Refund for Financial Year 2023

February 27, 2024

Decks in 2024